Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

solifenacin succinate 5 MG Oral Tablet [Vesicare]

Known as: SOLIFENACIN SUCCINATE 5 mg ORAL TABLET, FILM COATED [VESIcare], VESIcare 5 MG Oral Tablet 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Introduction and hypothesisTo determine the effectiveness of the muscarinic receptor antagonist solifenacin (VESIcare®) in the… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2016
2016
Background Radiotherapy is explicitly indicated as one of the excluding factors in diagnosing overactive bladder syndrome (OAB… Expand
  • table 1
  • table 2
  • figure 1
  • figure 3
  • figure 2
Is this relevant?
2014
2014
Abstract Purpose: Permanent and prolonged incontinence following robot assisted radical prostatectomy (RARP) is known to result… Expand
Is this relevant?
2014
2014
PURPOSE Permanent and prolonged incontinence following robot assisted radical prostatectomy (RARP) is known to result from injury… Expand
Is this relevant?
2006
2006
 
Is this relevant?
Review
2005
Review
2005
Muscarinic receptor antagonists such as oxybutynin and tolterodine are the most widely prescribed forms of treatment of the… Expand
Is this relevant?
2004
2004
ObjectiveSolifenacin succinate (YM905; Vesicare®) is a promising new bladder selective muscarinic receptor antagonist under… Expand
Is this relevant?